These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 18822426

  • 1. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment.
    Eiholzer U, Meinhardt U, Gallo C, Schlumpf M, Rousson V, l'Allemand D.
    J Pediatr; 2009 Feb; 154(2):225-9. PubMed ID: 18822426
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The musculoskeletal manifestations of Prader-Willi syndrome.
    Shim JS, Lee SH, Seo SW, Koo KH, Jin DK.
    J Pediatr Orthop; 2010 Jun; 30(4):390-5. PubMed ID: 20502241
    [Abstract] [Full Text] [Related]

  • 6. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE, Carrel AL, Whitman BY, Allen DB.
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
    Craig ME, Cowell CT, Larsson P, Zipf WB, Reiter EO, Albertsson Wikland K, Ranke MB, Price DA, KIGS International Board.
    Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
    [Abstract] [Full Text] [Related]

  • 8. Body composition in Prader-Willi syndrome compared with nonsyndromal obesity: Relationship to physical activity and growth hormone function.
    van Mil EG, Westerterp KR, Gerver WJ, Van Marken Lichtenbelt WD, Kester AD, Saris WH.
    J Pediatr; 2001 Nov; 139(5):708-14. PubMed ID: 11713451
    [Abstract] [Full Text] [Related]

  • 9. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
    Eiholzer U, Schlumpf M, Nordmann Y, l'Allemand D.
    J Pediatr Endocrinol Metab; 2001 Nov; 14 Suppl 6():1441-4. PubMed ID: 11837497
    [Abstract] [Full Text] [Related]

  • 10. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
    Carrel AL, Allen DB.
    J Pediatr Endocrinol Metab; 2001 Nov; 14 Suppl 6():1445-51. PubMed ID: 11837498
    [Abstract] [Full Text] [Related]

  • 11. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
    Höybye C.
    Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
    [Abstract] [Full Text] [Related]

  • 12. Clinical effects of treatment for hypogonadism in male adolescents with Prader-Labhart-Willi syndrome.
    Eiholzer U, Grieser J, Schlumpf M, l'Allemand D.
    Horm Res; 2007 Mar; 68(4):178-84. PubMed ID: 17374959
    [Abstract] [Full Text] [Related]

  • 13. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.
    Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB.
    J Pediatr; 2004 Dec; 145(6):744-9. PubMed ID: 15580194
    [Abstract] [Full Text] [Related]

  • 14. Analysis of NREM sleep in children with Prader-Willi syndrome and the effect of growth hormone treatment.
    Verrillo E, Bruni O, Franco P, Ferri R, Thiriez G, Pavone M, Petrone A, Paglietti MG, Crinò A, Cutrera R.
    Sleep Med; 2009 Jun; 10(6):646-50. PubMed ID: 19027358
    [Abstract] [Full Text] [Related]

  • 15. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
    Lindgren AC, Lindberg A.
    Horm Res; 2008 Jun; 70(3):182-7. PubMed ID: 18663319
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
    Allen DB, Carrel AL.
    J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
    [Abstract] [Full Text] [Related]

  • 17. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome.
    Eiholzer U, L'allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C.
    J Pediatr; 2004 Jun; 144(6):753-8. PubMed ID: 15192622
    [Abstract] [Full Text] [Related]

  • 18. Low dose growth hormone treatment in infants and toddlers with Prader-Willi syndrome is comparable to higher dosage regimens.
    Scheermeyer E, Harris M, Hughes I, Crock PA, Ambler G, Verge CF, Bergman P, Werther G, Craig ME, Choong CS, Davies PSW, PWS and OZGROW collaboration.
    Growth Horm IGF Res; 2017 Jun; 34():1-7. PubMed ID: 28427039
    [Abstract] [Full Text] [Related]

  • 19. The transition between the phenotypes of Prader-Willi syndrome during infancy and early childhood.
    Butler JV, Whittington JE, Holland AJ, McAllister CJ, Goldstone AP.
    Dev Med Child Neurol; 2010 Jun; 52(6):e88-93. PubMed ID: 20041936
    [Abstract] [Full Text] [Related]

  • 20. Growth hormone treatment of patients with Prader-Willi syndrome. Swedish Growth Hormone Advisory Group.
    Ritzén EM, Lindgren AC, Hagenäs L, Marcus C, Müller J, Blichfeldt S.
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():345-9. PubMed ID: 10698600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.